Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
LENZ

Price
13.04
Stock movement up
+0.16 (1.24%)
Company name
LENZ Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
408.02M
Ent value
399.40M
Price/Sales
23.23
Price/Book
2.10
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return (CAGR)
-47.50%
3 year return (CAGR)
80.44%
5 year return (CAGR)
-
10 year return (CAGR)
-
Last updated: 2026-02-20

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

LENZ does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales23.23
Price to Book2.10
EV to Sales22.74

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count31.29M
EPS (TTM)-2.06
FCF per share (TTM)-1.62

Income statement

Loading...
Income statement data
Revenue (TTM)17.57M
Gross profit (TTM)17.37M
Operating income (TTM)-67.90M
Net income (TTM)-58.88M
EPS (TTM)-2.06
EPS (1y forward)-3.03

Margins

Loading...
Margins data
Gross margin (TTM)98.90%
Operating margin (TTM)-386.54%
Profit margin (TTM)-335.21%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash25.40M
Net receivables0.00
Total current assets207.00M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment2.10M
Total assets210.70M
Accounts payable4.32M
Short/Current long term debt461.00K
Total current liabilities16.32M
Total liabilities16.78M
Shareholder's equity193.93M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-45.22M
Capital expenditures (TTM)938.00K
Free cash flow (TTM)-46.16M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-30.36%
Return on Assets-27.95%
Return on Invested Capital-30.36%
Cash Return on Invested Capital-23.80%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open12.75
Daily high13.31
Daily low12.56
Daily Volume355K
All-time high49.05
1y analyst estimate51.29
Beta-
EPS (TTM)-2.06
Dividend per share0.00
Ex-div date22 Mar 2024
Next earnings date-

Downside potential

Loading...
Downside potential data
LENZS&P500
Current price drop from All-time high-73.41%-1.82%
Highest price drop-93.98%-56.47%
Date of highest drop6 Jan 20239 Mar 2009
Avg drop from high-59.65%-10.84%
Avg time to new high58 days12 days
Max time to new high844 days1805 days
COMPANY DETAILS
LENZ (LENZ Therapeutics Inc) company logo
Marketcap
408.02M
Marketcap category
Small-cap
Description
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Employees
0
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...